New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill AJR120 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	~~1,2 C~~.~~36:2-472 and 36:2-473~~
	1	+	ASSEMBLY JOINT RESOLUTION No. 120 STATE OF NEW JERSEY 221st LEGISLATURE INTRODUCED FEBRUARY 5, 2024
2	2
3		-	~~1,2~~
	3	+	ASSEMBLY JOINT RESOLUTION
4	4
5		-	C.~~36:2-472~~
	5	+	No. 120
6	6
7		-	and 36:2-473
	7	+	STATE OF NEW JERSEY
	8	+
	9	+	221st LEGISLATURE
8	10
9	11
10	12
11		-	~~P.L. 2025~~, ~~Joint Resolution No. 2, approved March 6, 2025 Assembly Joint Resolution No. 120~~
	13	+	INTRODUCED FEBRUARY 5, 2024
12	14
13		-	P.L. 2025, Joint Resolution No. 2, approved March 6, 2025
14	15
15		-	Assembly Joint Resolution No. 120
	16	+
	17	+	Sponsored by: Assemblyman HERB CONAWAY, JR. District 7 (Burlington) SYNOPSIS Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. CURRENT VERSION OF TEXT As introduced.
	18	+
	19	+
	20	+
	21	+	Sponsored by:
	22	+
	23	+	Assemblyman HERB CONAWAY, JR.
	24	+
	25	+	District 7 (Burlington)
16	26
17	27
18	28
19	29
20	30
21		-	A Joint Resolution designating "Tardive Dyskinesia Awareness Week." Whereas, Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts; and Whereas, TD is an involuntary movement disorder caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression; and Whereas, Clinical research by the United States Food and Drug Administration has led to the availability of two treatments for adults with TD; and Whereas, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs); and Whereas, While prolonged treatment with these medications are often necessary to treat various illnesses that a person is experiencing, ongoing use of DRBAs can lead to the onset of TD; and Whereas, It is important that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association; and Whereas, It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed; and Whereas, TD is treatable if a patient receives timely screening and diagnosis; and Whereas, However, TD remains widely unknown and misunderstood due to a lack of public awareness and limited resources available to patients, providers, and caregivers; and Whereas, It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment which can lead to the onset of TD; and Whereas, Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment; and Whereas, People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society; and Whereas, To help ensure that people living with TD receive the care they need increased awareness is necessary at the State and federal level; and Whereas, A Tardive Dyskinesia Awareness Week would provide New Jerseyans with an annual reminder to check themselves for symptoms of the disorder and seek early medical intervention through annual screenings with their medical provider; now, therefore, Be It Resolved by the Senate and General Assembly of the State of New Jersey: 1. The first full week of May of each year is designated as "Tardive Dyskinesia Awareness Week" in NJ to encourage New Jerseyans to take preventative steps to identify the symptoms and risk factors of Tardive Dyskinesia. 2. The Governor is respectfully requested to annually issue a proclamation recognizing the first full week of May as "Tardive Dyskinesia Awareness Week" in New Jersey. 3. This joint resolution shall take effect immediately. STATEMENT This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD. It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment. Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ.
	31	+
	32	+
	33	+
	34	+
	35	+	SYNOPSIS
	36	+
	37	+	Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ.
	38	+
	39	+
	40	+
	41	+	CURRENT VERSION OF TEXT
	42	+
	43	+	As introduced.
	44	+
	45	+
	46	+
	47	+	A Joint Resolution designating "Tardive Dyskinesia Awareness Week." Whereas, Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts; and Whereas, TD is an involuntary movement disorder caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression; and Whereas, Clinical research by the United States Food and Drug Administration has led to the availability of two treatments for adults with TD; and Whereas, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs); and Whereas, While prolonged treatment with these medications are often necessary to treat various illnesses that a person is experiencing, ongoing use of DRBAs can lead to the onset of TD; and Whereas, It is important that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association; and Whereas, It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed; and Whereas, TD is treatable if a patient receives timely screening and diagnosis; and Whereas, However, TD remains widely unknown and misunderstood due to a lack of public awareness and limited resources available to patients, providers, and caregivers; and Whereas, It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment which can lead to the onset of TD; and Whereas, Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment; and Whereas, People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society; and Whereas, To help ensure that people living with TD receive the care they need increased awareness is necessary at the State and federal level; and Whereas, A Tardive Dyskinesia Awareness Week would provide New Jerseyans with an annual reminder to check themselves for symptoms of the disorder and seek early medical intervention through annual screenings with their medical provider; now, therefore, Be It Resolved by the Senate and General Assembly of the State of New Jersey: 1. The first full week of May of each year is designated as "Tardive Dyskinesia Awareness Week" in NJ to encourage New Jerseyans to take preventative steps to identify the symptoms and risk factors of Tardive Dyskinesia. 2. The Governor is respectfully requested to annually issue a proclamation recognizing the first full week of May as "Tardive Dyskinesia Awareness Week" in New Jersey. 3. This joint resolution shall take effect immediately. STATEMENT This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD. It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment.
22	48
23	49		A Joint Resolution designating "Tardive Dyskinesia Awareness Week."
24	50
25	51
26	52
27	53		Whereas, Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts; and
28	54
29	55		Whereas, TD is an involuntary movement disorder caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression; and
30	56
31	57		Whereas, Clinical research by the United States Food and Drug Administration has led to the availability of two treatments for adults with TD; and
32	58
33	59		Whereas, Many people with serious mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs); and
34	60
35	61		Whereas, While prolonged treatment with these medications are often necessary to treat various illnesses that a person is experiencing, ongoing use of DRBAs can lead to the onset of TD; and
36	62
37	63		Whereas, It is important that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association; and
38	64
39	65		Whereas, It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed; and
40	66
41	67		Whereas, TD is treatable if a patient receives timely screening and diagnosis; and
42	68
43	69		Whereas, However, TD remains widely unknown and misunderstood due to a lack of public awareness and limited resources available to patients, providers, and caregivers; and
44	70
45	71		Whereas, It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment which can lead to the onset of TD; and
46	72
47	73		Whereas, Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment; and
48	74
49	75		Whereas, People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society; and
50	76
51	77		Whereas, To help ensure that people living with TD receive the care they need increased awareness is necessary at the State and federal level; and
52	78
53	79		Whereas, A Tardive Dyskinesia Awareness Week would provide New Jerseyans with an annual reminder to check themselves for symptoms of the disorder and seek early medical intervention through annual screenings with their medical provider; now, therefore,
54	80
55	81
56	82
57	83		Be It Resolved by the Senate and General Assembly of the State of New Jersey:
58	84
59	85
60	86
61	87		1. The first full week of May of each year is designated as "Tardive Dyskinesia Awareness Week" in NJ to encourage New Jerseyans to take preventative steps to identify the symptoms and risk factors of Tardive Dyskinesia.
62	88
63	89
64	90
65	91		2. The Governor is respectfully requested to annually issue a proclamation recognizing the first full week of May as "Tardive Dyskinesia Awareness Week" in New Jersey.
66	92
67	93
68	94
69	95		3. This joint resolution shall take effect immediately.
70	96
71	97
72	98
73	99
74	100
75	101		STATEMENT
76	102
77	103
78	104
79	105		This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD.
80	106
81	107		It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment.
82		-
83		-
84		-
85		-
86		-
87		-
88		-
89		-
90		-
91		-	Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ.